

UNIVERSITI TEKNOLOGI MARA

**GUT HORMONE, ANTI-
INFLAMMATORY, ANTI-
OXIDATIVE AND QUALITY OF
LIFE OUTCOMES OF PROBIOTICS
MEDIATED GLYCAEMIC
CONTROL**

SYAMIMI BINTI SAMAH

PhD

May 2020

AUTHOR'S DECLARATION

I declare that the work in this thesis was carried out in accordance with the regulations of Universiti Teknologi MARA. It is original and is the results of my own work, unless otherwise indicated or acknowledged as referenced work. This thesis has not been submitted to any other academic institution or non-academic institution for any degree or qualification.

I, hereby, acknowledge that I have been supplied with the Academic Rules and Regulations for Post Graduate, Universiti Teknologi MARA, regulating the conduct of my study and research.

Name of Student : Syamimi binti Samah

Student I.D. No. : 2014716387

Programme : Doctor of Philosophy (Research)-PH990

Faculty : Pharmacy

Thesis Title : Gut hormone, Anti-inflammatory, Anti-oxidative and
Quality of Life Outcomes of Probiotics Mediated
Glycaemic Control

Signature of Student :

Date : May 2020

ABSTRACT

The rising prevalence of type 2 diabetes mellitus (T2DM) has called for alternatives and probiotics have been seen as viable option in managing T2DM effectively. The general aim of this thesis was to investigate the effects of probiotics on glycaemic control and QoL among T2DM patients. A systematic review and meta-analysis was first performed to identify the research gaps and to strengthen the experimental design for investigation of probiotic effects on glycaemic control and QoL amongst T2DM patients. A 15-item Diabetes Quality of Life Brief Inventory (DQoL-BCI) was then translated into Malay language and validated under Malaysian setting. A randomised controlled trial with 100 T2DM patients who were randomly assigned to receive either probiotics mixtures [Probio-Tec[®] 10⁹ Colony Forming Unit (CFU), Chr Hansen Holding A/S, Denmark] or placebo daily for 24 weeks was conducted. Blood sample were analyse to evaluate the hypoglycaemic, anti-inflammatory, anti-oxidative and gut hormone regulation effects of probiotics. The meta-analysis revealed a moderate beneficial hypoglycaemic effect of probiotics, with significant reduction in fasting blood glucose (FBG) (MD = -0.98 mmol/L; 95% CI: -1.17, 0.78, $p < 0.00001$). Probiotic effects on glycosylated haemoglobin (HbA_{1c}), anti-inflammatory and anti-oxidative markers remained inconsistent. Systematic review found existing clinical trials to be limited by variations in intervention duration, quality and depth of study design. For QoL validation study, exploratory factor analysis indicated that the 4-factor structure of the translated DQoL-BCI was optimal. Confirmatory factor analysis confirmed the 4-factor model fit. Cronbach's alpha coefficient and intraclass coefficient correlations (range) obtained were 0.703 and 0.86 (0.734 to 0.934), indicating good reliability and stability of the translated DQoL-BCI. There was negative, moderate correlation between the scores of DQoL-BCI (Malaysian version) and EQ-5D-3L utility score ($r = -0.329$, $p = 0.003$). The RCT revealed that glycaemic markers [i.e. HbA_{1c}, FBG, fasting insulin and Homeostatic Model Assessment-Insulin Resistance (HOMA-IR)] did not differ significantly between the groups. Insignificant findings were also observed in the inflammatory and oxidative stress markers except for significant increases in IL-10 ($\beta = 0.054$, 95%CI: 0.008 to 0.100, $p = 0.020$) and malondialdehyde (MDA) ($\beta = 0.064$, 95%CI: 0.006 to 0.121, $p = 0.031$) among patients receiving probiotics at week 24 for per-protocol (PP) population that completed the three time-points. GEE analyses showed that the increased levels of total cholesterol (TC) ($\beta = 0.234$, 95%CI: 0.029 to 0.439, $p = 0.025$) and LDL ($\beta = 0.178$, 95%CI: 0.002 to 0.354, $p = 0.047$) among patients receiving probiotics at week 24 was significant for PP population that completed the three time-points. Similar observations were also noted in the intention-to-treat (ITT). However, in the population that further excluded patients who were initiated with insulin, the changes in the abovementioned parameters became insignificant [i.e. MDA ($\beta = 0.049$, 95%CI: 0.004 to 0.103, $p=0.070$), TC ($\beta = 0.140$, 95%CI: 0.075 to 0.356, $p=0.201$) and LDL ($\beta = 0.103$, 95%CI: 0.080 to 0.285, $p=0.272$)] except for IL-10 ($\beta = 0.066$, 95%CI: 0.018 to 0.114, $p = 0.007$). DQoL score showed no significant changes across all time-points within or between the two groups. In summary, the findings from the present trial revealed that probiotics supplementation does not enhance glycaemic control (i.e. HbA_{1c}) and other parameters except for IL-10. The significant increase in IL-10 among intervention group provides fundamental data for future investigation on probiotics as alternative treatment in managing and preventing T2DM.

ACKNOWLEDGEMENT

In the name of God, the Most Merciful and The Most Gracious, all praises to Allah the Almighty for the strengths to complete this thesis. A huge appreciation goes to my supervisor; Dr Neoh Chin Fen, that only with her guidance that I could make this far. Thank you for believing in me and thank you for your infinite constructive comments and endless support that help me the most in getting through this challenging journey. I would also like to express my genuine gratitude to the co-supervisors; Associate Professor Dr Kalavathy Ramasamy, Dr Lim Siong Meng, Dr Nafiza Mat Nasir and Dr Noorhida Baharudin for lending out their expertise and for their encouraging suggestions throughout the time in making this thesis a reality. Not to forget, a special thanks to all the nurses, clinician and non-medical staffs at the UiTM Primary Care Clinic Selayang and UiTM Primary Care Clinic Sg. Buloh who helped me mostly in recruiting the patients and collection of data. Special thanks go to Chr Hansen Holding A/S, Denmark for their products sponsorship and not to forget the Malaysian Ministry of Education for the scholarship given. Also, my sincere acknowledgement goes to the Dean of Faculty of Pharmacy, Universiti Teknologi Mara Puncak Alam and the entire academic staffs that help me towards my postgraduate affairs. Next, sincere appreciation to all my Collaborative Drug Discovery Research (CDDR) colleagues especially Miss Yuganthini Vijayanathan, Miss Fatin Umirah Mahamad Hazaham, Miss Siti Hajar Rehiman, Mr Syukri Azman, Madam Siti Syakila Rohawi, Dr Faezah Sabirin, Madam Umi Khalsom Mohd Bajuri and Miss Naemah Md Hamzah for their countless assistance, guidance and support throughout my journey. Most importantly, a tremendous gratitude goes to my parents (Mr Samah Hasan and Mrs Hendon Abbas) whom with their endless prayers and loving support I was able to finish this thesis. Also, my heartfelt appreciation goes to my family and husband for simply believing in me all the way through this bumpy journey of mine. Lastly, I would also like to take this opportunity to thank everyone who has directly or indirectly facilitated in making this thesis a success. This thesis is for my late father, Mr Samah Hasan; the main reason why I pursued my PhD and to whom I promised to complete and dedicate this thesis before he left this world. Al-Fatihah.

TABLE OF CONTENTS

	Page
CONFIRMATION BY PANEL OF EXAMINERS	ii
AUTHOR'S DECLARATION	iii
ABSTRACT	iv
ACKNOWLEDGEMENT	v
TABLE OF CONTENTS	vi
LIST OF TABLES	x
LIST OF FIGURES	xi
LIST OF ABBREVIATIONS	xii
CHAPTER ONE INTRODUCTION	1
1.1 Research Background	1
1.2 Problem Statement	2
1.3 Objectives	3
1.4 Research Questions	4
CHAPTER TWO LITERATURE REVIEW	5
2.1 Diabetes Mellitus	5
2.1.1 Classification of Diabetes Mellitus	5
2.1.2 Pathophysiology of T2DM	7
2.1.3 Management and Treatment for T2DM	7
2.2 Gut Microbiota and T2DM	11
2.3 Probiotics	11
2.3.1 Probiotics and T2DM	12
2.3.2 <i>In vitro</i> and Cell culture studies	12
2.3.3 <i>In vivo</i> and Animal studies	13
2.3.4 Human clinical trials	25
2.4 Quality of Life	28